Show simple item record

dc.contributor.authorMorrissey, Hana
dc.contributor.authorBall, Patrick A
dc.contributor.authorAskari, Ayman
dc.contributor.authorNOURI, ABDULLA KHALID
dc.date.accessioned2019-11-19T14:47:25Z
dc.date.available2019-11-19T14:47:25Z
dc.date.issued2019-11-15
dc.identifier.citationAskari, A., Nouri, A. K., Morrissey, H. and Ball, P. A. (2019) Janus kinase enzyme (JAK) inhibitors and rheumatoid arthritis: a review of the literature, International Journal of Current Pharmaceutical Research, 11(6), pp. 11-14, doi:10.22159/ijcpr.2019v11i6.36343.en
dc.identifier.issn0975-7066en
dc.identifier.doi10.22159/ijcpr.2019v11i6.36343en
dc.identifier.urihttp://hdl.handle.net/2436/622933
dc.description.abstractCytokines play an essential role in normal cell growth and the regulation of immune function. The emergence of Janus Kinase Enzyme inhibitors promises the start of a revolution in the treatment of several chronic diseases. Their efficacy and safety profile have been demonstrated in multiple trials and they have been licensed for the treatment of a number of diseases including RA and PsA. Moreover, the use of highly selective Janus Kinase Enzyme inhibitors is currently being studied aiming to reduce side effects compared with traditional JAKinibs, an example of that would be the recent FDA approved upadacitinib. The Janus Kinase Enzyme inhibitorsmay supplant the classical biologic agents in the treatment of autoimmune diseases, since they exhibitthe advantages of oral administration, simultaneous blockade of multiple cytokines, reversibility and the lack of immunogenicity.en
dc.formatapplication/pdfen
dc.languageEnglish
dc.language.isoenen
dc.publisherInnovare Academic Sciencesen
dc.relation.urlhttps://innovareacademics.in/journals/index.php/ijcpr/article/view/36343en
dc.subjectCytokinesen
dc.subjectJanus Kinase Enzyme Inhibitorsen
dc.subjectJAKinibsen
dc.subjectJAKen
dc.subjectRHEUMATOID ARTHRITISen
dc.titleJanus kinase enzyme (JAK) inhibitors and rheumatoid arthritis: a review of the literatureen
dc.typeJournal articleen
dc.identifier.journalInternational Journal of Current Pharmaceutical Researchen
dc.date.updated2019-11-16T10:59:00Z
dc.date.accepted2019-10-10
rioxxterms.funderUniversity of Wolverhamptonen
rioxxterms.identifier.projectUOW19112019HMen
rioxxterms.versionVoRen
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by/4.0/en
rioxxterms.licenseref.startdate2019-11-19en
dc.source.volume11
dc.source.issue6
dc.source.beginpage11
dc.source.endpage14
refterms.dateFCD2019-11-19T14:47:15Z
refterms.versionFCDVoR
refterms.dateFOA2019-11-19T14:47:26Z


Files in this item

Thumbnail
Name:
36343-Article Text-168417-1-10 ...
Size:
275.4Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record

https://creativecommons.org/licenses/by/4.0/
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by/4.0/